First-line treatment of acute lymphoblastic leukemia with pegasparaginase.
Acute lymphoblastic leukemia (ALL) accounts for almost 4000 cases annually in the United States, approximately two thirds of which are in children and adolescents. Treatment results of ALL have improved considerably in the past decade, due to an optimal stratification of patients and a rational use of different antileukemic agents among which L-asparaginase (L-ASNase) plays a fundamental role. This drug has been used in pediatric ALL chemotherapy protocols for almost 3 decades. In the 1970s and 1980s a chemically modified form of this enzyme called pegasparaginase (PEG-ASNase) was rationally synthesized to decrease immunogenicity of the enzyme and prolong its half-life. The different advantages of PEG-ASNase have been demonstrated in many clinical studies, the last of which underline the utility of this drug in front-line therapy of ALL. In this review, we discuss the pharmacological advantages and clinical potential of PEG-ASNase and its important use in first-line treatment of ALL.
Masetti
Riccardo
R
Pediatric Oncology and Hematology Unit "Lalla Seràgnoli", University of Bologna, Bologna, Italy.
Pession
Andrea
A
Cancer Res. 1989 Aug 1;49(15):4363-8
2743326
Cancer Biochem Biophys. 1984 Jun;7(2):175-86
6467175
Pediatr Blood Cancer. 2006 Jan;46(1):18-25
15929133
Oncologist. 2007 Aug;12(8):991-8
17766659
Cancer. 1995 Mar 1;75(5):1176-81
7850718
Med Pediatr Oncol. 1979;7(4):335-40
296786
Am J Pediatr Hematol Oncol. 1979 Spring;1(1):9-13
295576
Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1474-8
8434007
Cancer Res. 1979 Oct;39(10):3893-6
383278
Cancer Res. 1977 Feb;37(2):535-40
264412
Blood. 2000 Jun 1;95(11):3310-22
10828010
Leukemia. 1989 Apr;3(4):294-7
2564453
Ann N Y Acad Sci. 1990;613:95-108
2076022
Leuk Lymphoma. 1993;10 Suppl:153-7
8481665
Br J Haematol. 2003 Dec;123(5):836-41
14632774
Leuk Lymphoma. 1993;10 Suppl:147-50
8481663
Crit Rev Oncol Hematol. 2007 Mar;61(3):208-21
17011787
Clin Cancer Res. 1999 Dec;5(12):4041-7
10632337
Eur J Pediatr. 1999 Dec;158 Suppl 3:S143-6
10650855
Blood. 2000 Sep 1;96(5):1709-15
10961868
Formulary. 1995 Jul;30(7):388-93
10151730
J Clin Oncol. 1993 Sep;11(9):1780-6
8355045
J Exp Med. 1953 Dec;98(6):565-82
13109110
Int J Cancer. 1992 Feb 20;50(4):644-8
1537631
Drugs. 2007;67(15):2153-71
17927282
Thromb Haemost. 2000 Jun;83(6):840-3
10896235
N Engl J Med. 1986 Sep 11;315(11):657-63
2943992
N Engl J Med. 2006 Mar 23;354(12):1323-4
16554542
Ann Intern Med. 1971 Jun;74(6):893-901
5281051
South Med J. 1987 Sep;80(9):1133-6
3306944
Blood. 2002 Apr 15;99(8):2734-9
11929760
Leukemia. 2008 Sep;22(9):1665-79
18580955
Cancer Treat Rep. 1979 Jun;63(6):1127-32
466651
Cancer Chemother Pharmacol. 2001;47(1):83-8
11221967
Jpn J Cancer Res. 1986 Dec;77(12):1264-70
3102431
Cancer Res. 1970 Sep;30(9):2297-305
4920133
J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26
15087948
Blood. 2007 Apr 1;109(7):2744-50
17132721
J Lab Clin Med. 1970 May;75(5):763-70
4909251
Essays Biochem. 1989;24:1-40
2676522
Br J Haematol. 1990 Apr;74(4):465-70
2189489
Expert Opin Pharmacother. 2007 Aug;8(12):1977-84
17696798
Expert Opin Biol Ther. 2009 Jan;9(1):111-9
19063697
J Exp Med. 1953 Dec;98(6):583-606
13109111
Ann Pharmacother. 1997 May;31(5):616-24
9161659
J Pediatr. 1982 Jun;100(6):990-5
6953222
Klin Padiatr. 2005 Nov-Dec;217(6):321-6
16307417
N Engl J Med. 2006 Jan 12;354(2):166-78
16407512
Cancer Treat Rev. 2002 Apr;28 Suppl A:13-6
12173407
BioDrugs. 2008;22(5):315-29
18778113
Blood. 2002 Mar 15;99(6):1986-94
11877270
Drug Metab Dispos. 1986 May-Jun;14(3):349-52
2872037
Leukemia. 2000 Mar;14(3):356-63
10720126
J Pharmacol Exp Ther. 1981 Feb;216(2):410-4
7007618
Med Pediatr Oncol. 1977;3(1):101-15
840159
J Clin Oncol. 2005 Oct 1;23(28):7161-7
16192600
J Clin Oncol. 1987 May;5(5):811-7
3572467
Eur J Pediatr. 1999 Dec;158 Suppl 3:S147-50
10650856
Leukemia. 1997 Nov;11(11):1858-61
9369418
Cancer Chemother Pharmacol. 2001 Jul;48(1):77-82
11488528
Leukemia. 2003 Nov;17(11):2254-6
14523472
Am J Pediatr Hematol Oncol. 1986 Summer;8(2):99-104
3526939
Cancer Chemother Pharmacol. 2002 Feb;49(2):149-54
11862429
J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):175-81
11990302
Blood. 2003 Dec 15;102(13):4541-6
12920041
Annu Rev Pharmacol. 1970;10:421-40
4911021
Biochemistry. 1969 Jun;8(6):2386-93
4895020
Blood. 2001 Mar 1;97(5):1211-8
11222362
Biochem Pharmacol. 1969 Oct;18(10):2578-80
4935103
Leukemia. 2004 Jun;18(6):1072-7
15057247
Med Pediatr Oncol. 1977;3(4):387-400
337095
Clin Pharmacokinet. 2005;44(4):367-93
15828851
Cancer. 1976 Oct;38(4):1515-23
991074
Biochim Biophys Acta. 1967 May 30;138(3):637-9
6036864
Biochem Biophys Res Commun. 1968 Apr 5;31(1):43-7
4869945
Cancer Chemother Pharmacol. 1993;32(4):310-4
8324873
Cancer. 1999 Oct 1;86(7):1203-9
10506705
Arch Biochem Biophys. 1964 May;105:450-2
14186753
N Engl J Med. 1969 Nov 6;281(19):1028-34
4898857
Biochemistry. 1970 Sep 1;9(18):3585-90
4928351
Hoppe Seylers Z Physiol Chem. 1980;361(2):105-17
6766894
Invest New Drugs. 1990 Feb;8(1):125-30
2345067
Cancer. 2007 Jul 1;110(1):103-11
17516438
Blood. 2007 May 15;109(10):4164-7
17264295
Br J Haematol. 2001 Apr;113(1):115-9
11328290
Haematologica. 2006 Jan;91(1):24-31
16434367
Anticancer Res. 1981;1(6):373-6
7046623
J Clin Oncol. 2000 Apr;18(7):1525-32
10735901
Semin Hematol. 2009 Jan;46(1):64-75
19100369
Biochemistry. 1967 Mar;6(3):721-30
5337885
Am J Physiol. 1997 May;272(5 Pt 1):C1691-9
9176161